TORONTO, Nov. 1, 2011 /CNW/ - Patheon Inc. (TSX: PTI), a leading
provider of contract development and manufacturing services to the
global pharmaceutical industry, announced today that Eric Evans,
Patheon's Executive Vice President and Chief Financial Officer, has
resigned from the company.
"Mr. Evans has helped to guide the creation and development of a company
strategy which is aimed at continuing our focus on customer service,
quality, scientific excellence and a commitment toward improving both
top line and bottom line growth. The Board and I thank Eric for his
considerable contributions to Patheon and wish him every success in the
future" stated Jim Mullen, CEO of Patheon.
Mullen continued, "Patheon is already seeing progress towards execution
of its new company strategy announced in September with specific focus
on efforts to further enhance capacity and look at costs. We have
commenced a search for our new CFO."
Until a new CFO has been appointed, Mr. Evan's duties will be managed by
Patheon's existing finance and operations teams.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, solid, semi-solid and liquid forms. The
company's integrated development and manufacturing network of 10
facilities, nine development centers and one clinical trial packaging
facility across North America and Europe, ensures that customer
products can be launched with confidence anywhere in the world.
SOURCE Patheon Inc.
For further information:
Investor Relations and Corporate Communications